Skip to main content
Premium Trial:

Request an Annual Quote

Galileo Genomics Raises $CA11.15 Million in Additional Equity Funding

NEW YORK, Jan.7 (GenomeWeb News) - Galileo Genomics has raised $CA11.15 million ($8.66 million) in additional equity funding, the company said today.

 

The December funding round includes new investor Carnegie Fund II of Stockholm, as well as existing investors HBM BioVentures of Zurich, MVI of Geneva, and Biofund of Helsinki.

 

This funding is in addition to $CA7.7 million the company raised last February.

 

Galileo, based in Montreal, plans to use the additional cash to identify genes associated with common and economically important diseases in the Quebec Founder Population using its chromozoom technology. Moreover, it wants to generate revenues from pharmacogenomics contracts.

 

Galileo focuses on analyzing DNA from the Quebec Founder Population, which it considers ideal for linkage disequilibrium-based genome-wide scans because of its low genetic variability and extensive genetic sharing.

 

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.